share_log

UBS Initiates Coverage On Fulgent Genetics With Neutral Rating, Announces Price Target of $35

UBS Initiates Coverage On Fulgent Genetics With Neutral Rating, Announces Price Target of $35

瑞銀以中性評級啓動對富金遺傳學的報道,宣佈目標股價爲35美元
Benzinga ·  2023/12/07 06:06

UBS analyst Dan Leonard initiates coverage on Fulgent Genetics (NASDAQ:FLGT) with a Neutral rating and announces Price Target of $35.

瑞銀分析師丹·倫納德以中性評級開始報道富爾金特遺傳學(納斯達克股票代碼:FLGT),並宣佈目標股價爲35美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論